Economic burden of respiratory diseases and chronic obstructive pulmonary disease in Russian Federation, 2016

The aim of this study was to evaluate economic burden of respiratory diseases and chronic obstructive pulmonary disease (COPD) in Russian Federation (RF) in 2016 including direct costs and economic losses caused by decreased labor efficiency. Methods. The analysis included direct cost, such as healthcare expenses and disablement payout, and economic losses due to decreased labor efficiency by the reason of morbidity and premature mortality. Data of Federal State Statistics Service, annual State Statistical Reports, the State Guarantee Program of Free Medical Care for Citizens of Russian Federation, and statistical data on respiratory diseases and COPD were used. Costs of medical care (ambulatory, hospital, and emergency care) were calculated based on compulsory health insurance tariffs. The amount of disability benefits payments was calculated based on number of disabled persons in each group and the size of the disability benefit. Indirect costs (or economic losses) included losses from non-produced products due to premature mortality and disability of working-aged adults. Results. In 2016, there were 623,000 years of potential life lost (YPLL) due to respiratory diseases, mainly in males. Of this, 35% of deaths and 22% of YPLL were related to COPD. Healthcare costs for COPD treatment included hospital care costs (83.9%), ambulatory care costs (11.1%) and emergency care costs (5%). In 2016, the economic burden of COPD in Russian Federation reached 170.3 billion ₽, or 18.8% of all losses and expenditures from respiratory diseases. This is 0.2% of the gross domestic product (GDP) in the same year. Conclusion. The economic burden of COPD in Russia in 2016 was 170.3 billion ₽, or 0.2% of GDP. The burden of COPD predominantly consisted of economic losses caused by premature mortality of working-aged subjects. These data suggest that priority should be given to measures aimed at preventing the occurrence and slowing down the progression of this disease, probably by increase the investment in the prevention and treatment of COPD. Such measures could reduce clinical and economic consequences of COPD.

respiratory diseases, chronic obstructive pulmonary disease, economic burden, healthcare expenses

1. Kolosov V.P., Manakov L.G., Kiku P.F., Polyanskaya E.V. [Respiratory disease at the Far East of Russia: epidemiological, social and hygienic aspects.]. Vladivostok: Dal'nauka; 2013 (in Russian).

2. Gambaryan M.G., Kalinina A.M., Shal'nova S.A. et al. [Epidemiology of chronic respiratory diseases in different climatic and geographic regions of Russia]. Pul'monologiya. 2014; (3): 55–61. DOI: 10.18093/0869-0189-2014-0-3-55-61 (in Russian).

3. Lamprecht B., McBurnie M.A., Vollmer W.M. et al. COPD in never smokers: results form the population-based burden of obstructive lung disease study. Chest. 2011; 139 (4): 752–763. DOI: 10.1378/chest.10-1253.

4. Halbert R.J., Natoli J.L., Gano A. et al. Global burden of COPD: systematic review and meta-analysis. Eur. Respir. J. 2006; 28 (3): 523–532. DOI: 10.1183/09031936.06.00124605.

5. Bousquet J., Dahl R., Khaltaev N. Global alliance against chronic respiratory diseases. Allergy. 2007; 62 (3): 216–223. DOI: 10.1111/j.1398-9995.2007.01307.x.

6. Mathers C.D., Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS. Med. 2006; 3 (11): 442. DOI: 10.1371/journal.pmed.0030442.

7. Eisner M.D., Anthonisen N., Coultas D. et al. An official American Thoracic Society public policy statement: Novel risk factors and the global burden of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2010; 182 (5): 693–718. DOI: 10.1164/rccm.200811-1757ST.

8. Salvi S.S., Barnes P.J. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009; 374 (9691): 733–743. DOI: 10.1016/S0140-6736(09)61303-9.

9. Chuchalin A.G., Khaltaev N., Antonov N.S. et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int. J. COPD. 2014; 9 (1): 963–74. DOI: 10.2147/COPD.S67283.

10. Chuchalin A.G., Avdeev S.N., Aisanov Z.R. et al. [Federal Clinical Guidelines on Diagnosis and Management of Chronic Obstructive Pulmonary Disease]. Pul'monologiya. 2014; (3): 15-54. DOI: 10.18093/0869-0189-2014-0-3-15-54 (in Russian).

11. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease. 2019 Report. Available at: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.6-FINAL-08Nov2018-wms.pdf

12. Semenova N.S., Balabina N.M. [Risk factors for development of chronic obstructive pulmonary disease]. Sibirskiy meditsinskiy zhurnal (Irkutsk). 2007; 72 (5): 8–11 (in Russian).

13. Trueman D., Woodcock F., Hancock E. Estimating the economic burden of respiratory illness in the UK. British Lung Foundation; 2017. Available at: https://www.blf.org.uk/policy/economic-burden

14. Ford E.S., Murphy L.B., Khavjou O. et al. Total and state-specific medical and absenteeism costs of COPD among adults aged 18 years in the United States for 2010 and projections through 2020. Chest. 2015; 147 (1): 31–45. DOI: 10.1378/chest.14-0972.

15. Pronina E.Yu. [The tip of the iceberg: COPD epidemiology (a review)]. Vestnik sovremennoy klinicheskoy meditsiny. 2011; 4 (3): 18–23. Available at: https://cyberleninka.ru/article/v/vershina-aysberga-epidemiologiya-hobl-obzor-literatury (in Russian).

16. Dan'kova L.R., Smagina T.N., Gromov V.V. [Primary disability due to chronic obstructive pulmonary disease in working-age population of the Orenburg region, 2008 – 2010]. Mediko-sotsial'nye problemy invalidnosti. 2012; (2): 69–73 (in Russian).

17. Karetnikova V.M., Karpova L.V., Petrunko LL. [Social and economic features of primary physical disability owing to respiratory diseases at the Irkutsk region]. Sibirskiy meditsinskiy zhurnal (Irkutsk). 2009; 90 (7): 180–183 (in Russian).

18. Srivastava K., Thakur D., Sharma S., Punekar Y.S. Systematic review of humanistic and economic burden of symptomatic chronic obstructive pulmonary disease. Pharmaco Economics. 2015; 33 (5): 467–488. DOI: 10.1007/s40273-015-0252-4.

19. Kontsevaya A. N., Drapkina O. M., Balanova Yu. A. et al. [Economic burden of cardiovascular diseases in Russian Federation, 2016]. Ratsional'naya farmakoterapiya v kardiologii. 2018; 14 (2): 156–166. DOI: 10.20996/1819-6446-2018-14-2-156-166 (in Russian).

20. Anzueto A., Sethi S., Martinez F.J. Exacerbations of chronic obstructive pulmonary disease. Proc. Am. Thorac. Soc. 2007; 4 (7): 554–564. DOI: 10.1513/pats.200701-003FM.

21. Manakov L.G., Polyanskaya E.V. [Socio-economic burden of respiratory diseases]. Byulleten' fiziologii i patologii dykhaniya. 2011; 42: 70–72. Available at: http://www.cyberleninka.ru/article/n/sotsialno-ekonomicheskiy-uscherb-ot-bolezney-organov-dyhaniya (in Russian).

22. Krysanov I.S. [Cost analysis of chronic obstructive pulmonary disease in Russian Federation]. Kachestvennaya klinicheskaya praktika. 2014; (2): 51–56. Available at: https://cyberleninka.ru/article/n/analiz-stoimosti-hronicheskoy-obstruktivnoy-bolezni-lyogkih-v-rossiyskoy-federatsii (in Russian).

23. Guarascio A.J., Ray S.M., Finch C.K., Self T.H. The clinical and economic burden of chronic obstructive pulmonary disease in the USA. Clinicoecon. Outcomes Res. 2013; 5: 235–245. DOI: 10.2147/CEOR.S34321.

24. Mannino D.M., Buist A.S. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007; 370 (9589): 765–773. DOI: 10.1016/S0140-6736(07)61380-4.

25. Rabe K.F., Hurd S., Anzueto A. et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176 (6): 532–555. DOI: 10.1164/rccm.200703-456SO.

26. Mannino D.M., Higuchi K., Yu T.C. et al. Economic burden of COPD in the presence of comorbidities. Chest. 2015; 148 (1): 138–150. DOI: 10.1378/chest.14-2434.